First inhibitor of enzyme long thought to be potential drug target for fighting disease-causing parasites and bacteria is identified.
Collaboration aimed at generating multiple clinical product candidates for various blood and solid tumor cancers
Biotech says actions will reposition the company as a top-tier ERT developer and save it $4 million annually.
The University of Texas MD Anderson Cancer Center will join with Pfizer to study novel combinations of three of the pharma giant’s immuno-oncology candidates and other Pfizer treatments for solid and blood cancers
Fujikura Kasei is exercising its previously agreed-upon option to license Cellmid’s midkine (MK) diagnostic technology, paying out a JPY 40 million (approximately $400,000) milestone fee.
Biogen will partner with Vir Biotechnology to advance the development and clinical manufacturing of Vir’s human monoclonal antibodies as potential treatments for COVID-19.
A technique developed by researchers at Scripps Research seeks to identify useful tumor-infiltrating immune cells more quickly and precisely. The method, called FucoID, is named after the enzyme fucosyltransferase that "tags" the surface of sought-after immune cells so they can be seen and captured.
ImmuNext entered into an agreement with Sanofi to develop a novel protein for the treatment of autoimmune disorders